PSA
35
-2
GD
64
-2
NKE
39
3
HIG
63
-4
FOX
70
2
NSC
42
-3
MAT
54
4
IRM
49
2
TGT
57
5
ALL
57
-3
FMC
16
6
CA
36
12
GWW
62
-3
HRL
36
-2
SJM
16
2
RHI
38
3
KMI
63
-2
LNC
68
-2
KLAC
72
-2
F
56
-2
PSA
35
-2
GD
64
-2
NKE
39
3
HIG
63
-4
FOX
70
2
NSC
42
-3
MAT
54
4
IRM
49
2
TGT
57
5
ALL
57
-3
FMC
16
6
CA
36
12
GWW
62
-3
HRL
36
-2
SJM
16
2
RHI
38
3
KMI
63
-2
LNC
68
-2
KLAC
72
-2
F
56
-2
Financhill
Back

Santen Pharmaceutical Co., Ltd. 10K Form

Buy
51

SNPHY
Santen Pharmaceutical Co., Ltd.

Last Price:
$10.58
Seasonality Move:
-2.29%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SNPHY News And Ratings

See the #1 stock for the next 7 days that we like better than SNPHY

SNPHY Financial Statistics

Sales & Book Value

Annual Sales: $2B
Cash Flow: $-10.1M
Price / Cash Flow: 17.82
Annual Sales: $5.73
Price / Book: 1.83

Profitability

EPS (TTM): 0.61940
Net Income (TTM): $207.2M
Gross Margin: $1.1B
Return on Equity: 10.89%
Return on Assets: 7.62%

Santen Pharmaceutical Co., Ltd. Earnings Forecast

Key Santen Pharmaceutical Co., Ltd. Financial Ratios

  • The Gross Profit Margin over the past 35 years for SNPHY is 54.40%.
  • The Selling, General & Administrative Expenses for SNPHY have been equal to 29.32% of Gross Profit Margin.
  • The Research & Development expenses have been 7.82% of Revenue.
  • The Interest Expense is 3.02% of Operating Income.
  • The Net Earning history of SNPHY is 11.95% of Total Revenues.
  • Per Share Earnings over the last 35 years have been positive in 19 years.

Santen Pharmaceutical Co., Ltd. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: SNPHY
Website: santen.co.jp

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 2.65
Quick Ratio: 1.72

Price-to-Earnings

Trailing P/E Ratio: 15.56
Forward P/E Ratio: 0

SNPHY Technical Analysis vs Fundamental Analysis

Buy
51
Santen Pharmaceutical Co., Ltd. (SNPHY) is a Buy

Is Santen Pharmaceutical Co., Ltd. a Buy or a Sell?